COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00043134
Recruitment Status : Unknown
Verified April 2008 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : April 13, 2010
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Decitabine may help myelodysplasia cells develop into normal stem cells. It is not yet known if decitabine is more effective than standard supportive care in treating myelodysplastic syndrome.

PURPOSE: Randomized phase III trial to compare the effectiveness of low-dose decitabine with that of standard supportive care in treating older patients who have myelodysplastic syndrome.

Condition or disease Intervention/treatment Phase
Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Drug: decitabine Phase 3

Detailed Description:


  • Compare the efficacy of low-dose decitabine vs standard supportive care, in terms of overall survival, of elderly patients with myelodysplastic syndromes.
  • Compare the response rate and progression-free survival of patients treated with these regimens.
  • Determine the toxicity of decitabine in these patients.
  • Assess the duration of hospitalization and number of blood transfusions in patients treated with these regimens.
  • Assess the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to cytogenetic risk factors (good vs poor vs intermediate vs unknown), disease (primary myelodysplastic syndrome (MDS) vs secondary MDS), and participating center. Patients with a successful cytogenetic exam are also stratified according to overall International Prognostic Scoring System score (intermediate 1 vs intermediate 2 vs high risk). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive decitabine IV over 4 hours every 8 hours for 3 days. Treatment repeats every 6 weeks for 4-8 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive standard supportive care. Quality of life is assessed at baseline, every 6 weeks during therapy, every 2 months for 1 year, and then every 3 months thereafter.

Patients are followed every 2 months for 1 year and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 220 patients (110 per treatment arm) will be accrued for this study within 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study
Study Start Date : May 2002
Estimated Primary Completion Date : May 2008

Primary Outcome Measures :
  1. Duration of overall survival

Secondary Outcome Measures :
  1. Best response rate as measured by Cheson response criteria
  2. Overall progression-free survival
  3. Toxicity as assessed by CTC v2.0
  4. Quality of life as assessed by EORTC QLQ30
  5. Days in Hospital

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of primary or secondary myelodysplastic syndromes (MDS)

    • Any FAB or WHO criteria cellular type allowed
  • Bone marrow blast count on aspiration or biopsy of 1 of the following:

    • No more than 10% with poor cytogenetic risk factors (defined as any numerical or structural abnormality of chromosome 7 and/or complex abnormalities)
    • 11-20%
    • 21-30% for patients with acute myeloid leukemia (AML) secondary to MDS (i.e., refractory anemia with excess blasts in transformation by FAB classification)
    • Patients who failed the cytogenetic exam are allowed provided bone marrow blasts are at least 5% and/or 2-3 cytopenias are present
  • No rapid progression towards full-blown AML
  • No blast crisis of chronic myeloid leukemia
  • No t(8;21) alone or in combination with other abnormalities
  • Ineligible for intensive chemotherapy (e.g., cytarabine or an anthracycline)



  • 60 and over

Performance status

  • WHO 0-2

Life expectancy

  • Not specified


  • See Disease Characteristics


  • Bilirubin less than 1.5 times upper limit of normal (ULN)
  • Hepatitis B surface antigen negative


  • Creatinine less than 1.5 times ULN


  • No severe cardiovascular disease
  • No arrhythmias requiring chronic treatment
  • No congestive heart failure
  • No New York Heart Association class III or IV heart disease
  • No symptomatic ischemic heart disease


  • HIV negative
  • No active uncontrolled infection
  • No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix within the past 2 years
  • No prior or concurrent evidence of CNS or psychiatric disorders requiring hospitalization
  • No psychological, familial, sociological, or geographical condition that would preclude study


Biologic therapy

  • More than 6 weeks since prior growth factors for primary MDS
  • No concurrent antiangiogenic drugs (e.g., thalidomide)
  • No concurrent interleukin, interferon, or anti-thymocyte globulin


  • See Disease Characteristics
  • More than 6 weeks since prior hydroxyurea for primary MDS
  • No other prior chemotherapy for MDS or AML
  • Prior chemotherapy for solid tumors or lymphoma (resulting in secondary MDS) allowed

Endocrine therapy

  • No concurrent steroids (except as inhalation therapy)


  • Prior radiotherapy for solid tumors or lymphoma (resulting in secondary MDS) allowed


  • Not specified


  • More than 6 weeks since prior immunosuppressive agents for primary MDS
  • No concurrent amifostine
  • No concurrent cyclosporine
  • No other concurrent experimental therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00043134

Show Show 46 study locations
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Layout table for investigator information
OverallOfficial: Pierre W. Wijermans, MD, PhD HagaZiekenhuis - Locatie Leyenburg
OverallOfficial: Michael Luebbert, MD University Hospital Freiburg
Publications of Results:
WijerMans P, Suciu S, Baila L, et al.: Low dose decitabine versus best supportive sare in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomizedpPhase III study (06011) of the EORTC Leukemia and German MDS Study Groups. [Abstract] Blood 112 (11): A-226, 2008.

Layout table for additonal information Identifier: NCT00043134    
Other Study ID Numbers: CDR0000256224
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: April 13, 2010
Last Verified: April 2008
Keywords provided by National Cancer Institute (NCI):
chronic myelomonocytic leukemia
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
refractory anemia
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
refractory anemia with ringed sideroblasts
refractory cytopenia with multilineage dysplasia
secondary myelodysplastic syndromes
atypical chronic myeloid leukemia, BCR-ABL negative
myelodysplastic/myeloproliferative neoplasm, unclassifiable
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors